These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17766111)

  • 21. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways.
    Vijapurkar U; Wang W; Herbst R
    Cancer Res; 2007 Jan; 67(1):237-45. PubMed ID: 17210704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds.
    Zhao GD; Wan RZ; Liu ZP
    Curr Med Chem; 2014; 21(23):2691-701. PubMed ID: 24606497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors.
    Jiang C; Yang L; Wu WT; Guo QL; You QD
    Bioorg Med Chem; 2011 Sep; 19(18):5612-27. PubMed ID: 21856161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
    Cox CD; Garbaccio RM
    Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator.
    Luo L; Carson JD; Molnar KS; Tuske SJ; Coales SJ; Hamuro Y; Sung CM; Sudakin V; Auger KR; Dhanak D; Jackson JR; Huang PS; Tummino PJ; Copeland RA
    J Am Chem Soc; 2008 Jun; 130(24):7584-91. PubMed ID: 18491908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.
    Song H; Zhou S; Wang R; Li S
    ChemMedChem; 2013 Nov; 8(11):1736-49. PubMed ID: 23964020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydropyrazole and dihydropyrrole structures based design of Kif15 inhibitors as novel therapeutic agents for cancer.
    Sebastian J
    Comput Biol Chem; 2017 Jun; 68():164-174. PubMed ID: 28355588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present).
    Jiang C; You Q
    Expert Opin Ther Pat; 2013 Dec; 23(12):1547-60. PubMed ID: 23978071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
    Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
    Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.
    Garbaccio RM; Fraley ME; Tasber ES; Olson CM; Hoffman WF; Arrington KL; Torrent M; Buser CA; Walsh ES; Hamilton K; Schaber MD; Fernandes C; Lobell RB; Tao W; South VJ; Yan Y; Kuo LC; Prueksaritanont T; Slaughter DE; Shu C; Heimbrook DC; Kohl NE; Huber HE; Hartman GD
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1780-3. PubMed ID: 16439122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of inhibition of human KSP by ispinesib.
    Lad L; Luo L; Carson JD; Wood KW; Hartman JJ; Copeland RA; Sakowicz R
    Biochemistry; 2008 Mar; 47(11):3576-85. PubMed ID: 18290633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
    Lange JH; van der Neut MA; den Hartog AP; Wals HC; Hoogendoorn J; van Stuivenberg HH; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1752-7. PubMed ID: 20137935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
    Tunquist BJ; Woessner RD; Walker DH
    Mol Cancer Ther; 2010 Jul; 9(7):2046-56. PubMed ID: 20571074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel ATP-competitive kinesin spindle protein inhibitors.
    Parrish CA; Adams ND; Auger KR; Burgess JL; Carson JD; Chaudhari AM; Copeland RA; Diamond MA; Donatelli CA; Duffy KJ; Faucette LF; Finer JT; Huffman WF; Hugger ED; Jackson JR; Knight SD; Luo L; Moore ML; Newlander KA; Ridgers LH; Sakowicz R; Shaw AN; Sung CM; Sutton D; Wood KW; Zhang SY; Zimmerman MN; Dhanak D
    J Med Chem; 2007 Oct; 50(20):4939-52. PubMed ID: 17725339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of inhibitor binding to human kinesin spindle protein by site-directed mutagenesis.
    Marshall CG; Torrent M; Williams O; Hamilton KA; Buser CA
    Arch Biochem Biophys; 2009 Apr; 484(1):1-7. PubMed ID: 19467625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteomic analysis of annexin A2 phosphorylation induced by microtubule interfering agents and kinesin spindle protein inhibitors.
    Fernandez-Garcia B; Casado P; Prado MA; Ugarte-Gil LJ; Artime N; Cabal-Hierro L; Calvo E; López JA; Ramos S; Lazo PS
    J Proteome Res; 2010 Sep; 9(9):4649-60. PubMed ID: 20597553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5.
    Schiemann K; Finsinger D; Zenke F; Amendt C; Knöchel T; Bruge D; Buchstaller HP; Emde U; Stähle W; Anzali S
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1491-5. PubMed ID: 20149654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore identification of KSP inhibitors.
    Liu F; You QD; Chen YD
    Bioorg Med Chem Lett; 2007 Feb; 17(3):722-6. PubMed ID: 17095225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and structure-activity relationships of 3,5-diaryl-1H-pyrazoles as inhibitors of arylamine N-acetyltransferase.
    Fullam E; Talbot J; Abuhammed A; Westwood I; Davies SG; Russell AJ; Sim E
    Bioorg Med Chem Lett; 2013 May; 23(9):2759-64. PubMed ID: 23518278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationships and molecular docking of novel dihydropyrimidine-based mitotic Eg5 inhibitors.
    Prokopcová H; Dallinger D; Uray G; Kaan HY; Ulaganathan V; Kozielski F; Laggner C; Kappe CO
    ChemMedChem; 2010 Oct; 5(10):1760-9. PubMed ID: 20737530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.